{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:13Z","timestamp":1786980373527,"version":"build-2736575974"},"reference-count":38,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Liver Journal"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This umbrella review synthesizes evidence from meta-analyses and reviews comparing transarterial chemoembolization (TACE) combined with sorafenib versus monotherapy for unresectable hepatocellular carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following PRIOR guidelines, PubMed, Google Scholar, Web of Science, and Embase were searched from inception to December 2024. Outcomes included overall survival (OS), time to progression (TTP), disease control rate (DCR), and objective response rate (ORR). Corrected covered area (CCA) assessed overlap, and methodological quality was evaluated using AMSTAR-2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 13,821 records, 9 meta-analyses were included, with substantial overlap (CCA: 49%). Eight reviews assessed OS; five reported a significant survival benefit (hazard ratio [HR] 0.62\u20130.74,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), while two found no significant effect (HR 0.75\u20130.97,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt; 0.05). Eight evaluated TTP; six showed a significant reduction in risk (HR 0.61\u20130.75,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.05), while two reported non-significant findings (HR 0.74\u20130.77,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &gt; 0.05). Four assessed DCR; two reported a significant benefit (odds ratio [OR] 0.52\u20134.72,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.01), one showed a non-significant trend (OR: 1.57,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.06), and one found no significant effect (relative risk [RR] 1.04,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.57). Six assessed ORR; three reported a significant increase in response (OR 2.19\u20133.59,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.01), one showed a significant reduction (OR 0.85,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001), one found no significant effect (RR 1.20,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.26), and one reported a significant protective effect (OR 0.39,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TACE plus sorafenib improves TTP, ORR, and OS in unresectable HCC and highlights the need for personalized treatment and further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3138\/canlivj-2025-0044","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:49:22Z","timestamp":1784321362000},"page":"488-500","source":"Crossref","is-referenced-by-count":0,"title":["Transarterial chemoembolization combined with sorafenib versus monotherapy for unresectable hepatocellular carcinoma: An umbrella review of meta-analyses"],"prefix":"10.3138","volume":"9","author":[{"given":"Vikash Kumar","family":"Karmani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Fatima","family":"Murtaza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Paz","family":"Aviles","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Universidad Del Valle de Mexico, Queretaro, Qro. Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyashish","family":"Bhardwaj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Advent Health, Orlando, Florida, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araj Naveed","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"Dar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Punjab, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalam","family":"Sohal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Institute Northwest, Seattle, Washington, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"crossref","unstructured":"Llovet JM Kelley RK Villanueva A . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3. Medline: 33479224","DOI":"10.1038\/s41572-020-00240-3"},{"key":"e_1_3_10_3_2","doi-asserted-by":"crossref","unstructured":"Sung H Ferlay J Siegel RL . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660. Medline: 33538338","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","unstructured":"Siegel RL Miller KD Fuchs HE Jemal A. Cancer statistics 2021. CA Cancer J Clin. 2021;71(1):7\u201333. Medline: 33433946","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_10_5_2","doi-asserted-by":"crossref","unstructured":"Chen LC Chiou WY Lin HY . Comparing stereotactic ablative radiotherapy versus re-transcatheter arterial chemoembolization for hepatocellular carcinoma patients with incomplete response after initial TACE (TASABR): a randomized controlled trial. BMC Cancer. 2019;19:275. https:\/\/doi.org\/10.1186\/s12885\u2013019\u20135488-z. Medline: 30922261","DOI":"10.1186\/s12885-019-5461-3"},{"key":"e_1_3_10_6_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer. EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"e_1_3_10_7_2","doi-asserted-by":"crossref","unstructured":"Bruix J Reig M Rimola J . Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54(6):2238\u201344. https:\/\/doi.org\/10.1002\/hep.24670. Medline: 21932394","DOI":"10.1002\/hep.24670"},{"key":"e_1_3_10_8_2","doi-asserted-by":"crossref","unstructured":"Escudier B Worden F Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19(2):177\u201389. https:\/\/doi.org\/10.1080\/14737140.2019.1561280. Medline: 30575405","DOI":"10.1080\/14737140.2019.1559058"},{"key":"e_1_3_10_9_2","doi-asserted-by":"crossref","unstructured":"Tanaka S Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009;100(1):1\u20138. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.01001.x. Medline: 19038007","DOI":"10.1111\/j.1349-7006.2008.01006.x"},{"key":"e_1_3_10_10_2","doi-asserted-by":"crossref","unstructured":"Llovet JM Ricci S Mazzaferro V . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857. Medline: 18650514","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_10_11_2","doi-asserted-by":"crossref","unstructured":"Pollock M Fernandes RM Pieper D . Preferred reporting items for overviews of reviews (PRIOR): a protocol for the development of a reporting guideline for overviews of reviews of healthcare interventions. Systematic Reviews. 2019;8(1):335. https:\/\/doi.org\/10.1186\/s13643-019-1252-9. Medline: 31870434","DOI":"10.1186\/s13643-019-1252-9"},{"key":"e_1_3_10_12_2","doi-asserted-by":"crossref","unstructured":"Shea BJ Reeves BC Wells G . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008. Medline: 28935701","DOI":"10.1136\/bmj.j4008"},{"key":"e_1_3_10_13_2","doi-asserted-by":"crossref","unstructured":"Pieper D Antoine S-L Mathes T Neugebauer EAM Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.11.007. Medline: 24581293","DOI":"10.1016\/j.jclinepi.2013.11.007"},{"key":"e_1_3_10_14_2","doi-asserted-by":"crossref","unstructured":"Lencioni R Crocetti L. Local\u2013regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43\u201358. https:\/\/doi.org\/10.1148\/radiol.11110144. Medline: 22190656","DOI":"10.1148\/radiol.11110144"},{"key":"e_1_3_10_15_2","doi-asserted-by":"crossref","unstructured":"Chao Y Chung YH Han G . The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136(6):1458\u201367. https:\/\/doi.org\/10.1002\/ijc.29168. Medline: 25099027","DOI":"10.1002\/ijc.29126"},{"key":"e_1_3_10_16_2","doi-asserted-by":"crossref","unstructured":"Kudo M Ueshima K Ikeda M . Randomised multicentre prospective trial of transarterial chemoembolisation plus sorafenib vs transarterial chemoembolisation alone in hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492\u2013501. https:\/\/doi.org\/10.1136\/gutjnl-2019-318934. Medline: 31801872","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"e_1_3_10_17_2","doi-asserted-by":"crossref","unstructured":"Pratama MY Pascut D Massi MN Tiribelli C. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med. 2019;7(20):577. https:\/\/doi.org\/10.21037\/atm.2019.09.31. Medline: 31807558","DOI":"10.21037\/atm.2019.09.142"},{"key":"e_1_3_10_18_2","doi-asserted-by":"crossref","unstructured":"Zheng L Guo C Chen C . Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term retrospective study. Oncotarget. 2017;8(58):97613\u201322. https:\/\/doi.org\/10.18632\/oncotarget.17531. Medline: 29228637","DOI":"10.18632\/oncotarget.18811"},{"key":"e_1_3_10_19_2","doi-asserted-by":"crossref","unstructured":"Xie Y Tian H Xiang B . Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate\u2013advanced hepatocellular carcinoma. Medicine (Baltimore). 2021;100(33):e26958. https:\/\/doi.org\/10.1097\/MD.0000000000026958. Medline: 34414963","DOI":"10.1097\/MD.0000000000026958"},{"key":"e_1_3_10_20_2","doi-asserted-by":"crossref","unstructured":"Chen A Li S Yao Z . Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2020;36(2):302\u201310. https:\/\/doi.org\/10.1111\/jgh.15180. Medline: 32652685","DOI":"10.1111\/jgh.15180"},{"key":"e_1_3_10_21_2","doi-asserted-by":"crossref","unstructured":"Cheng Z He L Guo Y Song Y Song S Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib for advanced hepatocellular carcinoma: a meta-analysis. World J Surg Oncol. 2020;18(1):166. https:\/\/doi.org\/10.1186\/s12957\u2013020\u201302017\u20130.","DOI":"10.1186\/s12957-020-02017-0"},{"key":"e_1_3_10_22_2","doi-asserted-by":"crossref","unstructured":"Zeng J Li L Mei Z. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40(6):688\u201397. https:\/\/doi.org\/10.1016\/j.clinre.2016.04.006. Medline: 27339594","DOI":"10.1016\/j.clinre.2016.04.006"},{"key":"e_1_3_10_23_2","doi-asserted-by":"crossref","unstructured":"Zhang X Wang K Wang M . Transarterial chemoembolization combined with sorafenib versus TACE alone for hepatocellular carcinoma with portal vein tumor thrombus. Oncotarget. 2017;8(17):29416\u201327. https:\/\/doi.org\/10.18632\/oncotarget.15075. Medline: 28177886","DOI":"10.18632\/oncotarget.15075"},{"key":"e_1_3_10_24_2","doi-asserted-by":"crossref","unstructured":"Wang G Liu Y Zhou S-F . Sorafenib combined with transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10(3):501\u201310. https:\/\/doi.org\/10.1007\/s12072-015-9700-7. Medline: 26856326","DOI":"10.1007\/s12072-015-9700-7"},{"key":"e_1_3_10_25_2","doi-asserted-by":"crossref","unstructured":"Fu Q-H Zhang Q Bai X-L . Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(8):1429\u201340. https:\/\/doi.org\/10.1007\/s00432-014-1684-5. Medline: 24770582","DOI":"10.1007\/s00432-014-1684-5"},{"key":"e_1_3_10_26_2","doi-asserted-by":"crossref","unstructured":"Jin P-P Shao S-Y Wu W-T . Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis. Jpn J Clin Oncol. 2018;48(12):1058\u201369. https:\/\/doi.org\/10.1093\/jjco\/hyy138. Medline: 30272196","DOI":"10.1093\/jjco\/hyy138"},{"key":"e_1_3_10_27_2","doi-asserted-by":"crossref","unstructured":"Li L Zhao W Wang M . Transarterial chemoembolization plus sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Gastroenterology. 2018;18(1):138. https:\/\/doi.org\/10.1186\/s12876-018-0849-0. Medline: 30180810","DOI":"10.1186\/s12876-018-0849-0"},{"key":"e_1_3_10_28_2","unstructured":"Hu M-D Jia L-H Liu H-B Zhang K-H Guo G-H. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Eur Rev Med Pharmacol Sci. 2016;20(1):64\u201374. Medline: 26813455"},{"key":"e_1_3_10_29_2","doi-asserted-by":"crossref","unstructured":"Yang M Yuan J-Q Bai M Han G-H. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Mol Biol Rep. 2014;41(10):6575\u201382. https:\/\/doi.org\/10.1007\/s11033-014-3541-7. Medline: 25091939","DOI":"10.1007\/s11033-014-3541-7"},{"key":"e_1_3_10_30_2","doi-asserted-by":"crossref","unstructured":"Kim GH Choi SL Kim JH Shim JH Alali M Kim N. Sorafenib combined with chemoembolization for locally advanced hepatocellular carcinoma with macroscopic vascular invasion: a propensity score analysis. Life (Basel). 2021;11(10):1066. https:\/\/doi.org\/10.3390\/life11101066. Medline: 34685437","DOI":"10.3390\/life11101066"},{"key":"e_1_3_10_31_2","doi-asserted-by":"crossref","unstructured":"Meng L Li H Ji Y . Efficacy safety and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study. Cancer Immunol Immunother. 2024;74(1):79\u201390. https:\/\/doi.org\/10.1007\/s00262-024-03857-5. Medline: 39499356","DOI":"10.1007\/s00262-024-03857-5"},{"key":"e_1_3_10_32_2","doi-asserted-by":"crossref","unstructured":"Finn RS Qin S Ikeda M . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745. Medline: 32402160","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_10_33_2","doi-asserted-by":"crossref","unstructured":"Kudo M Finn RS Qin S . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1. Medline: 29433850","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_3_10_34_2","doi-asserted-by":"crossref","unstructured":"Bruix J Qin S Merle P . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised double-blind placebo-controlled phase 3 trial. Lancet. 2017;389(10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9. Medline: 27932229","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"e_1_3_10_35_2","doi-asserted-by":"crossref","unstructured":"Reig M Forner A Rimola J . BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018. Medline: 34801630","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"e_1_3_10_36_2","doi-asserted-by":"crossref","unstructured":"Yao Q Zhang H Xiong B Zheng C. Combination of sorafenib and TACE inhibits portal vein invasion for intermediate-stage hepatocellular carcinoma: a single-center retrospective controlled study. Oncotarget. 2017;8(45):79012\u201322. https:\/\/doi.org\/10.18632\/oncotarget.20745. Medline: 29108283","DOI":"10.18632\/oncotarget.20745"},{"key":"e_1_3_10_37_2","doi-asserted-by":"crossref","unstructured":"Liu K Min X-L Peng J Yang K Yang L Zhang X-M. The changes of HIF-1\u03b1 and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297\u2013302. https:\/\/doi.org\/10.14740\/jocmr2496w. Medline: 26985249","DOI":"10.14740\/jocmr2496w"},{"key":"e_1_3_10_38_2","doi-asserted-by":"crossref","unstructured":"Kudo M. Immune checkpoint inhibitors plus anti-VEGF\/tyrosine kinase inhibitors combined with TACE (triple therapy) in unresectable hepatocellular carcinoma. Liver Cancer. 2024;13(3):227\u201334. https:\/\/doi.org\/10.1159\/000538558. Medline: 38894813","DOI":"10.1159\/000538558"},{"key":"e_1_3_10_39_2","doi-asserted-by":"crossref","unstructured":"Monge C Xie C Steinberg SM Greten TF. Clinical indicators for long-term survival with immune checkpoint therapy in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:507\u201312. https:\/\/doi.org\/10.2147\/JHC.S311496. Medline: 34104639","DOI":"10.2147\/JHC.S311496"}],"container-title":["Canadian Liver Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/canlivj-2025-0044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:41:15Z","timestamp":1786977675000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/canlivj-2025-0044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.3138\/canlivj-2025-0044"],"URL":"https:\/\/doi.org\/10.3138\/canlivj-2025-0044","relation":{},"ISSN":["2561-4444"],"issn-type":[{"value":"2561-4444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}